Novartis Ag

Novartis Pharma Gmbh

Markus Wartmann

Terence O'Reilly

Pamela Cohen

Manuel Litchman

John David Rothermel

Pascal Furet

Jeanette Marjorie Wood

Robin Alec Fairhurst

Robert Mah

Carl-Henrik Heldin

Bo Han

Matthew J LaMarche

Peter Traxler

Catherine Leblanc

Can Wang

Jorge Garcia Fortanet

Lv Liao

Jing Xiong

Nicole Buschmann

Joerg Kallen

Dale Porter

Edwige Liliane Jeanne Lorthiois

Diana Graus Porta

Xianglin Zhao

Nicolas Soldermann

Holger Sellner

Bahaa Salem

Thomas Knoepfel

Ralf Brandt

Vincent Bordas

Elisabeth Buchdunger

Kristian Pietras

TianLing Chen

Diane Greeley

Arne Östman

Patrick Chène

Tobias Schmelzle

Patricia Imbach-weese

Nafeeza Hafeez

Cara Brocklehurst

Vito Guagnano

Markus Voegtle

Joseph McKENNA

Mickael Le Douget

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;

Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations

The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NR, wherein Ris hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

Combinations comprising epothilones and pharmaceutical uses thereof

The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Cancer treatment with epothilones

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Combination comprising a signal transduction inhibitor and an epothilone derivative

Growing community of inventors

Riehen, Switzerland

Markus Wartmann